A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

NIR-II Light Accelerated Prodrug Reduction of Pt(IV)-Incorporating Pseudo Semiconducting Polymers for Robust Degradation and Maximized Photothermal/Chemo-Immunotherapy. | LitMetric

AI Article Synopsis

  • Selective activation of Pt(IV) prodrugs in tumors minimizes damage to normal tissues, but current methods face challenges with control and light penetration.
  • The study introduces a new polymer, PSP-Pt, using Stille polymerization that integrates a Pt(IV) prodrug activated by NIR-II light, enhancing cancer treatment.
  • In mouse models with CT26 colon cancer, the NIR-II irradiated nanoparticles promote the reduction of Pt(IV) to oxaliplatin, effectively killing cancer cells through a combination of photothermal and chemo-immunotherapy effects.

Article Abstract

Selective activation of Pt(IV) prodrugs within tumors is particularly attractive because of their low damage to normal tissues. However, current common activation via chemical/photoreduction of Pt(IV) prodrugs into Pt(II) counterparts is limited by undesirable spatial-temporal control over this reduction process and the ineffective tissue penetration depth of undesirable light. Here, a pseudo-conjugated-polymer is designed via Stille polymerization, resulting in PSP-Pt with a Pt(IV) prodrug of oxaliplatin (Oxa(IV)) in the polymer main chain that can be activated by NIR-II light. PSP-Pt can co-assemble with a commercially available lipid polymer, namely mPEG -DSPE, into NP . Under 1064 nm light irradiation, NP can be photoactivated to accelerate the Pt(IV) reduction to release oxaliplatin, thereby killing the cancer cells by photothermal effect and chemo-immunotherapy inside a mouse model with CT26 colon cancer. This work reports the application of NIR-II light for accelerating Pt(IV) reduction for cancer tumor therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1002/adma.202300048DOI Listing

Publication Analysis

Top Keywords

nir-ii light
12
ptiv prodrugs
8
ptiv reduction
8
ptiv
5
light accelerated
4
accelerated prodrug
4
reduction
4
prodrug reduction
4
reduction ptiv-incorporating
4
ptiv-incorporating pseudo
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!